血清补充因子5a水平与不同严重程度的阿尔茨海默病患者的炎症反应和认知功能之间的相关性
Zhilian Li1, Huifang Wu2, Yi Luo1
1Department of Neurology, The First People´s Hospital of Jingzhou City, No.8 HangKong Road, Shashi District, 434100, Jingzhou City, Hubei Province, P.R. China.
BMC neurology
|September 7, 2023
概括
血清补充因子5a (C5a) 水平随着阿尔茨海默病 (AD) 严重程度的增加而增加,并与炎症和认知功能下降相关. 升高的C5a是AD进展的危险因素.
科学领域:
- 神经科学是一个神经科学.
- 免疫学 免疫学 免疫学
- 生物化学 生物化学
背景情况:
- 阿尔茨海默病 (AD) 是导致痴呆的主要原因.
- 血清补充因子5a (C5a) 越来越多地与阿尔茨海默病的发病有关.
- 这项研究调查了C5a水平与AD严重程度之间的关联.
研究的目的:
- 探索血清C5a水平在不同程度的阿尔茨海默病患者中的作用.
- 评估C5a,促炎性标志物和AD中的认知功能之间的相关性.
- 确定C5a作为AD恶化的潜在风险因素.
主要方法:
- 血清C5a和促炎因素 (TNF-α,IL-1β,IL-6,CRP) 在轻度,中度,重度AD患者和对照中使用ELISA进行测量.
- 认知功能使用微型心理状态检查 (MMSE) 评分进行评估.
- 统计分析包括皮尔森相关性,物流回归,ROC曲线和卡普兰-梅尔分析.
主要成果:
- 在AD患者中,血清中C5a,TNF-α,IL-1β,IL-6和CRP的水平升高,并且随着疾病的严重程度而增加.
- 与轻度/中度AD患者相比,严重AD患者的C5a和炎症标志物水平较高.
- 血清C5a水平与炎症标志物正相关,与MMSE得分负相关,并被确定为AD恶化的独立风险因素.
结论:
- 血清C5a水平随着阿尔茨海默氏症严重程度的增加而上升.
- C5a表达与促炎因子水平积极相关,与认知功能负相关.
- 血清C5a升高可能表明严重AD进展的风险更高.
关键词:
阿尔茨海默氏症是阿尔茨海默氏症的一种疾病.认知功能 认知功能补充因子 5a 的补充因子.炎症反应是一种炎症反应.卡普兰-梅耶尔公司后勤多变量回归的逻辑回归.皮尔森的测试测试测试.接收器的运行特征曲线.更多相关视频
06:23The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease
Published on: October 13, 2016
32.4K
07:30Evaluation of the Cognitive Performance of Hypertensive Patients with Silent Cerebrovascular Lesions
Published on: April 23, 2021
3.1K
相关概念视频
Alzheimer's Disease: Overview
517
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
517
Alzheimer's Disease: Treatment
212
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
212
Dementia
139
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
139
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests
13
Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
13
